Tag Archives: Cory Kasimov

J.P. Morgan Keeps Their Hold Rating on Biogen (BIIB)

In a report issued on June 18, Cory Kasimov from J.P. Morgan maintained a Hold rating on Biogen (BIIB – Research Report). The company’s shares closed last Friday at $271.00. According to TipRanks.com, Kasimov is a 5-star analyst with an

J.P. Morgan Sticks to Its Hold Rating for Gilead Sciences (GILD)

In a report released today, Cory Kasimov from J.P. Morgan maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $85.00. The company’s shares closed last Tuesday at $77.95. According to TipRanks.com, Kasimov is

J.P. Morgan Believes Moderna (NASDAQ: MRNA) Won’t Stop Here

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Moderna (MRNA – Research Report) on May 7 and set a price target of $60.00. The company’s shares closed last Tuesday at $64.38, close to its 52-week high of $67.67.

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Theratechnologies (NASDAQ: THTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moderna (MRNA – Research Report) and Theratechnologies (THTX – Research Report) with bullish sentiments. Moderna (MRNA) J.P. Morgan analyst Cory Kasimov maintained

J.P. Morgan Believes Gilead Sciences (NASDAQ: GILD) Won’t Stop Here

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed last Friday at $82.68, close to its 52-week high of $85.98. According to TipRanks.com, Kasimov is a 5-star analyst

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (NASDAQ: ACAD), Tilray (NASDAQ: TLRY) and Aimmune Therapeutics (NASDAQ: AIMT)

Analysts fell to the sidelines weighing in on ACADIA Pharmaceuticals (ACAD – Research Report), Tilray (TLRY – Research Report) and Aimmune Therapeutics (AIMT – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the